» Articles » PMID: 12072489

AIDS Vaccination Studies Using an Ex Vivo Feline Immunodeficiency Virus Model: Failure to Protect and Possible Enhancement of Challenge Infection by Four Cell-based Vaccines Prepared with Autologous Lymphoblasts

Overview
Journal J Virol
Date 2002 Jun 20
PMID 12072489
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Immunogenicity and protective activity of four cell-based feline immunodeficiency virus (FIV) vaccines prepared with autologous lymphoblasts were investigated. One vaccine was composed of FIV-infected cells that were paraformaldehyde fixed at the peak of viral expression. The other vaccines were attempts to maximize the expression of protective epitopes that might become exposed as a result of virion binding to cells and essentially consisted of cells mildly fixed after saturation of their surface with adsorbed, internally inactivated FIV particles. The levels of FIV-specific lymphoproliferation exhibited by the vaccinees were comparable to the ones previously observed in vaccine-protected cats, but antibodies were largely directed to cell-derived constituents rather than to truly viral epitopes and had very poor FIV-neutralizing activity. Moreover, under one condition of testing, some vaccine sera enhanced FIV replication in vitro. As a further limit, the vaccines proved inefficient at priming animals for anamnestic immune responses. Two months after completion of primary immunization, the animals were challenged with a low dose of homologous ex vivo FIV. Collectively, 8 of 20 vaccinees developed infection versus one of nine animals mock immunized with fixed uninfected autologous lymphoblasts. After a boosting and rechallenge with a higher virus dose, all remaining animals became infected, thus confirming their lack of protection.

Citing Articles

Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development.

Bigay J, Le Grand R, Martinon F, Maisonnasse P Front Microbiol. 2022; 13:932408.

PMID: 36033843 PMC: 9399815. DOI: 10.3389/fmicb.2022.932408.


Vaccine- and natural infection-induced mechanisms that could modulate vaccine safety.

Kostoff R, Kanduc D, Porter A, Shoenfeld Y, Calina D, Briggs M Toxicol Rep. 2020; 7:1448-1458.

PMID: 33110761 PMC: 7581376. DOI: 10.1016/j.toxrep.2020.10.016.


FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge.

Miller C, Emanuelli M, Fink E, Musselman E, Mackie R, Troyer R NPJ Vaccines. 2018; 3:16.

PMID: 29736270 PMC: 5928050. DOI: 10.1038/s41541-018-0051-y.


Applications of the FIV Model to Study HIV Pathogenesis.

Miller C, Abdo Z, Ericsson A, Elder J, VandeWoude S Viruses. 2018; 10(4).

PMID: 29677122 PMC: 5923500. DOI: 10.3390/v10040206.


The Comparative Value of Feline Virology Research: Can Findings from the Feline Lentiviral Vaccine Be Translated to Humans?.

Hosie M, Techakriengkrai N, Beczkowski P, Harris M, Logan N, Willett B Vet Sci. 2017; 4(1).

PMID: 29056666 PMC: 5606627. DOI: 10.3390/vetsci4010007.


References
1.
Kang C, Hariharan K, Nara P, Sodroski J, Moore J . Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. J Virol. 1994; 68(9):5854-62. PMC: 236990. DOI: 10.1128/JVI.68.9.5854-5862.1994. View

2.
Laube L, Burrascano M, Dejesus C, Howard B, Johnson M, Lee W . Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins. Hum Gene Ther. 1994; 5(7):853-62. DOI: 10.1089/hum.1994.5.7-853. View

3.
Frey S, Marsh M, Gunther S, Pelchen-Matthews A, Stephens P, Ortlepp S . Temperature dependence of cell-cell fusion induced by the envelope glycoprotein of human immunodeficiency virus type 1. J Virol. 1995; 69(3):1462-72. PMC: 188734. DOI: 10.1128/JVI.69.3.1462-1472.1995. View

4.
Elder J, Phillips T . Feline immunodeficiency virus as a model for development of molecular approaches to intervention strategies against lentivirus infections. Adv Virus Res. 1995; 45:225-47. DOI: 10.1016/s0065-3527(08)60062-7. View

5.
Matteucci D, Pistello M, Mazzetti P, Giannecchini S, Del Mauro D, Zaccaro L . Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies. J Virol. 1996; 70(1):617-22. PMC: 189855. DOI: 10.1128/JVI.70.1.617-622.1996. View